ConductScience.org, home

Paper34249367

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.

Cadegiani FA and 3 others. New Microbes New Infect, 2021. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. Papers, record 34249367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34249367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.
PubMed
Journal
New Microbes New Infect
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.5
iCite
Revised in PubMed
2024-08-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cadegiani FAF A
2Goren AA
3Wambier CGC G
4McCoy JJ

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132360780Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19.Clin Microbiol Infect2020https://conductscience.org/library/papers/32360780PubMed
234128772Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials.Pathog Glob Health2021https://conductscience.org/library/papers/34128772PubMed
332901263Post COVID Syndrome (PCS) and healthcare workers: who cares for the carers?QJM2020https://conductscience.org/library/papers/32901263PubMed
432444366Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.BMJ2020https://conductscience.org/library/papers/32444366PubMed
514983848International ethical guidelines for biomedical research involving human subjects.Bull Med Ethics2002https://conductscience.org/library/papers/14983848PubMed
632007143Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet2020https://conductscience.org/library/papers/32007143PubMed
733643746
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).
Cureus2021https://conductscience.org/library/papers/33643746PubMed
834084102Natural History and Clinical Course of Symptomatic and Asymptomatic COVID-19 Patients in the Kingdom of Saudi Arabia.Saudi J Med Med Sci2021https://conductscience.org/library/papers/34084102PubMed
932609307Excess Deaths From COVID-19 and Other Causes, March-April 2020.JAMA2020https://conductscience.org/library/papers/32609307PubMed
1032451119The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic.Mayo Clin Proc2020https://conductscience.org/library/papers/32451119PubMed
1132459916Hospitalization and Mortality among Black Patients and White Patients with Covid-19.N Engl J Med2020https://conductscience.org/library/papers/32459916PubMed
1233480414From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?J Travel Med2021https://conductscience.org/library/papers/33480414PubMed
1334146226Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review.Qual Life Res2021https://conductscience.org/library/papers/34146226PubMed
1433903131Prophylaxis against covid-19: living systematic review and network meta-analysis.BMJ2021https://conductscience.org/library/papers/33903131PubMed
1533635829Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study.Eur J Endocrinol2021https://conductscience.org/library/papers/33635829PubMed
1634145166Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.Am J Ther2021https://conductscience.org/library/papers/34145166PubMed
1732031570Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.JAMA2020https://conductscience.org/library/papers/32031570PubMed
1833089570Clinical symptoms of hyperandrogenic women diagnosed with COVID-19.J Eur Acad Dermatol Venereol2021https://conductscience.org/library/papers/33089570PubMed
1932725286Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?J Genet Eng Biotechnol2020https://conductscience.org/library/papers/32725286PubMed
2034167876Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis.Eur J Intern Med2021https://conductscience.org/library/papers/34167876PubMed

See all 61 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
41884792Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study).Ther Adv Infect Dis2026https://conductscience.org/library/papers/41884792PubMed
38197085Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.Clin Pharmacol2024https://conductscience.org/library/papers/38197085PubMed
37337731Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients.J Intensive Care Med2023https://conductscience.org/library/papers/37337731PubMed
36143420Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.Life (Basel)2022https://conductscience.org/library/papers/36143420PubMed
35898916Microbiome-Based Hypothesis on Ivermectin's Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity.Front Microbiol2022https://conductscience.org/library/papers/35898916PubMed
35889004Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.Microorganisms2022https://conductscience.org/library/papers/35889004PubMed
35726131Ivermectin for preventing and treating COVID-19.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/35726131PubMed
35359702Can anti-parasitic drugs help control COVID-19?Future Virol2022https://conductscience.org/library/papers/35359702PubMed
35299698Ivermectin and the Integrity of Healthcare Evidence During COVID-19.Front Public Health2022https://conductscience.org/library/papers/35299698PubMed
35163830Blood Bacteria-Free DNA in Septic Mice Enhances LPS-Induced Inflammation in Mice through Macrophage Response.Int J Mol Sci2022https://conductscience.org/library/papers/35163830PubMed
34976549
Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.
Cureus2021https://conductscience.org/library/papers/34976549PubMed
34823008ESCMID COVID-19 living guidelines: drug treatment and clinical management.Clin Microbiol Infect2022https://conductscience.org/library/papers/34823008PubMed
34822026NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?Inflammopharmacology2022https://conductscience.org/library/papers/34822026PubMed
34679203Antibiotics for the treatment of COVID-19.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/34679203PubMed
34375047Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.Am J Ther2021https://conductscience.org/library/papers/34375047PubMed
34318930Ivermectin for preventing and treating COVID-19.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/34318930PubMed
34145166Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.Am J Ther2021https://conductscience.org/library/papers/34145166PubMed
34088250NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.Expert Rev Anti Infect Ther2022https://conductscience.org/library/papers/34088250PubMed
33437562The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort.Cureus2021https://conductscience.org/library/papers/33437562PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DPP41803PubTator's text mininghttps://conductscience.org/library/genes/1803NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
OLFM410562PubTator's text mininghttps://conductscience.org/library/genes/10562NCBI Gene
SLC25A1883733PubTator's text mininghttps://conductscience.org/library/genes/83733NCBI Gene
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524NCBI Gene
TMPRSS27113PubTator's text mininghttps://conductscience.org/library/genes/7113NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34249367

GET https://conductscience.org/api/papers/v1/34249367/references?page=2